DECEMBER 202319TECH OUTLOOKBut the innovation of Medtack truly shines in the subsequent phase, where AI comes into play. Medtack's AI capabilities transform the arduous task of medical record review into an efficient process, distilling hundreds of pages to highlight critical inclusion criteria. This pinpoint accuracy aids human reviewers in verifying candidate eligibility and later managing digital medical records.This strategic data handling at their fingertips effectively dismantles the traditional bottlenecks associated with paper-based or siloed digital processes, accelerating the trial timeline.The Medtack Edge for StartupsFor startups looking to penetrate the market rapidly, Medtack emerges as an indispensable ally. The primary challenge most startup innovators face is adhering to the stringent recruitment deadlines of phase II and III clinical trials. It's a common scenario: they depend on clinical sites' assurances of timely recruitment, only to encounter delays that can derail their market access plans.Credent Partners provides a lifeline via its proprietary Medtack Research Portal for trial sites. Through this portal research coordinators get access to consent-ready candidates, to their medical records, and to an AI-generated report that summarizes whether the candidate meets selection criteria, eliminating the most common bottlenecks that mar the recruitment process. Additionally the portal empowers site coordinators by providing workflow management tools, and secure text messaging so they can more effectively communicate with candidates.Credent Partners' Medtack Research Portal offers trial sites streamlined access to qualified participants. This innovative platform provides research coordinators with immediate access to consent-ready candidates, their medical histories, and AI-generated eligibility summaries, streamlining the recruitment process and addressing common bottlenecks. Moreover, the portal enhances site coordinators' efficiency with workflow management tools and secure messaging, facilitating better communication with candidates and accelerating the consent process.Many clients attest to Medtack's substantial impact, with reports of speeding up the recruitment process by up to 70 percent--a more than impressive statistics in the fast-paced startup ecosystem.From Words to ActionThe company consistently achieves transformative results in clinical trial patient recruitment, as evidenced by its successful partnership portfolio. Clients praise the platform for its intuitive design, ease of use, and tangible outcomes. A collaboration with CVRx Inc., one of Credent Partners' first clients, is a prime example. Faced with recruitment hurdles for its groundbreaking heart failure device trial, CVRx turned to Credent Partners. The team's key role in the timely enrollment of the pivotal trial led to the FDA approval of CVRx's Barostim device in 2019. In fact, CVRx's management team was so pleased with the services that, to this day, they continue to rely on Credent Partners' Medtack platform to design and implement their direct-to-patient commercial strategy.Another exciting case that Credent Partners' is currently working on involves an Israeli startup that developed a revolutionary implantable device to treat the symptoms of benign prostatic hyperplasia without sexual side effects. Despite a very rough start to their recruitment campaign, the introduction of the Medtack platform resulted in a quick turnaround. Within three months, they were able to increase the recruitment rate seven-fold, steering the trial back on track.Quantitative data from various trials using Medtack exhibit a pattern of increased recruitment efficiency as well as improvements in candidate pool quality. This data serves as tangible proof of Medtack's impact and commitment to surmounting hurdles in the demanding clinical trial recruitment landscape. Medtack stands out through its integration of advanced CRM and AI technologies, along with targeted social media and search engine strategies
< Page 9 | Page 11 >